STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVMD
  4. [Form 4] Revolution Medicines, Inc. Insider Trading Activity

RVMD Chief Medical Officer's Planned Stock Sale Shows Continued Large Holdings

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Revolution Medicines (RVMD) Chief Medical Officer Wei Lin reported insider trading activity on June 16, 2025. The transaction involved the sale of 2,173 shares at a weighted average price of $39.83 per share, executed through multiple trades ranging from $39.60 to $39.83.

The sale was conducted under a Rule 10b5-1 trading plan established on December 23, 2024, specifically to address tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Lin maintains beneficial ownership of 90,499 shares, which includes:

  • 1,021 shares acquired through the Employee Stock Purchase Plan on May 31, 2025
  • 64,800 restricted stock units (RSUs)

This transaction represents a planned sale for tax purposes rather than a discretionary trading decision by the insider, as evidenced by the pre-established 10b5-1 plan.

Positive

  • None.

Negative

  • None.
Insider Wei Lin
Role Chief Medical Officer
Sold 2,173 shs ($87K)
Type Security Shares Price Value
Sale Common Stock 2,173 $39.83 $87K
Holdings After Transaction: Common Stock — 90,499 shares (Direct)
Footnotes (4)
  1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.
  2. F2. This transaction was executed in multiple trades in prices ranging from $39.6017 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. F3. Includes 1,021 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
  4. F4. Includes 64,800 RSUs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

How many shares of RVMD stock did CMO Wei Lin sell on June 16, 2025?
Wei Lin sold 2,173 shares of RVMD common stock on June 16, 2025 at a weighted average price of $39.83 per share.

What was the purpose of Wei Lin's RVMD stock sale in June 2025?
The sale was made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024, specifically to satisfy Lin's tax withholding obligation upon the vesting of restricted stock units (RSUs) after March 15, 2025.

How many RVMD shares does Wei Lin own after the June 2025 transaction?
Following the transaction, Wei Lin beneficially owns 90,499 shares, which includes 1,021 shares acquired through the Employee Stock Purchase Plan on May 31, 2025 and 64,800 RSUs.

What was the price range of RVMD shares sold by Wei Lin in the June 2025 transaction?
The shares were sold in multiple trades at prices ranging from $39.6017 to $39.8291, with a weighted average sale price of $39.83 per share.

When did RVMD's CMO Wei Lin establish the 10b5-1 trading plan?
Wei Lin established the Rule 10b5-1 instruction letter on December 23, 2024, which governed this transaction executed on June 16, 2025.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wei Lin
(Last) (First) (Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/16/2025 S(1) 2,173 D $39.83(2) 90,499(3)(4) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after March 15, 2025.
2. This transaction was executed in multiple trades in prices ranging from $39.6017 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. Includes 1,021 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
4. Includes 64,800 RSUs.
/s/ Jack Anders, as Attorney-in-fact for Wei Lin 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR